Weight Watchers Partners with AHA for Healthy Living BEYOND Weight Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: Newsfilter
- Research Collaboration: Weight Watchers is partnering with the American Heart Association to promote the Healthy Living BEYOND Weight™ Study, aimed at gaining insights into the lived experiences and long-term health outcomes of individuals with obesity, thereby enhancing scientific understanding and support for weight management.
- Integrated Care Model: Weight Watchers offers a comprehensive care model that combines medical support, nutritional guidance, and behavioral change, particularly for members using GLP-1 medications, helping them achieve significant results and improve overall health.
- Behavioral Support Impact: Data shows that GLP-1 users engaged in Weight Watchers' behavioral support program lost an average of 61.3% more weight at one month and 29.1% more at twelve months, highlighting the importance of integrating behavioral support to significantly enhance weight loss outcomes.
- Community Engagement: The Healthy Living BEYOND Weight™ Study is open to U.S. adults, and Weight Watchers leverages its strong community network to ensure more individuals can participate in research, ultimately improving obesity management and health care across various communities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WW
Wall Street analysts forecast WW stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 15.780
Low
38.00
Averages
38.00
High
38.00
Current: 15.780
Low
38.00
Averages
38.00
High
38.00
About WW
WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Weight Watchers Partners with AHA for Healthy Living BEYOND Weight Study
- Research Collaboration: Weight Watchers is partnering with the American Heart Association to promote the Healthy Living BEYOND Weight™ Study, aimed at gaining insights into the lived experiences and long-term health outcomes of individuals with obesity, thereby enhancing scientific understanding and support for weight management.
- Integrated Care Model: Weight Watchers offers a comprehensive care model that combines medical support, nutritional guidance, and behavioral change, particularly for members using GLP-1 medications, helping them achieve significant results and improve overall health.
- Behavioral Support Impact: Data shows that GLP-1 users engaged in Weight Watchers' behavioral support program lost an average of 61.3% more weight at one month and 29.1% more at twelve months, highlighting the importance of integrating behavioral support to significantly enhance weight loss outcomes.
- Community Engagement: The Healthy Living BEYOND Weight™ Study is open to U.S. adults, and Weight Watchers leverages its strong community network to ensure more individuals can participate in research, ultimately improving obesity management and health care across various communities.
See More
WW (WW) Q4 2025 Earnings Call Transcript
See More
WW International Shares Surge 11% as Galloway Capital Discloses 8.42% Stake
- Investor Stake Increase: Galloway Capital disclosed an 8.42% stake in WW International, leading to an 11% surge in the company's stock price, indicating a market reassessment of its brand and long-term strategic potential.
- Leadership Transition: Following the abrupt departure of CEO Tara Comonte, WW International quickly established an interim CEO office led by CFO Felicia DellaFortuna and COO Jonathan Volkmann, ensuring operational continuity during this transition.
- Future Opportunities: Galloway emphasized that WW International has the chance to recruit a “transformational” CEO with expertise in consumer health, digital wellness, and subscription-based healthcare platforms, which could further drive the company's growth.
- Shareholder Value: Galloway believes WW International is worth significantly more than its current trading value and looks forward to engaging constructively with the board and management team to help unlock shareholder value.
See More
Weight Watchers Launches Ozempic® Pill for Diabetes Care
- New Drug Launch: Weight Watchers announced the addition of Novo Nordisk's Ozempic® pill through its Med+ program, further expanding its portfolio of oral GLP-1 treatments aimed at providing more options for adults with type 2 diabetes, thereby enhancing its competitive edge in the market.
- Insurance Coverage Advantage: The widespread insurance coverage of Ozempic® allows eligible members to access monthly prescription costs as low as $25, which not only reduces the financial burden on patients but also increases Weight Watchers' appeal in the diabetes management sector.
- Clinical Support System: The Weight Watchers Med+ program offers FDA-approved Ozempic® along with support from a professional clinical team, assisting members in navigating insurance and daily management, thus improving treatment outcomes.
- Significant Health Outcomes: In a study of 136 participants, the Weight Watchers diabetes nutrition program resulted in a 0.75% reduction in HbA1c levels after six months, demonstrating the program's effectiveness in improving health for diabetes patients and further solidifying Weight Watchers' market position.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
WW Plans to Prepay $40 Million Loan Ahead of Earnings Report
- Debt Prepayment: WW plans to utilize up to $40 million in cash to prepay its outstanding term loan, thereby reducing its debt burden, and expects to generate cash flow during the 'peak season marketing,' enhancing the company's financial stability.
- Q1 Expectations: Fiscal AI estimates a Q1 loss per share of $2.05 on revenue of $158.5 million, while full-year revenue is still projected between $620 million and $635 million, demonstrating the company's ability to maintain revenue stability amid challenges.
- Leadership Changes: WW recently experienced the abrupt departure of CEO Tara Comonte, and while the company is still searching for a new CEO, this change may impact strategic execution and market confidence.
- Retail Trader Reaction: On Stocktwits, retail sentiment about WW shifted from 'bullish' to 'extremely bullish,' with messaging volumes tripling over the last 24 hours, indicating a positive market response to the company's debt reduction efforts.
See More
Weight Watchers Partners with AHA for Healthy Living BEYOND Weight Study
- Research Collaboration: Weight Watchers is partnering with the American Heart Association to promote the Healthy Living BEYOND Weight™ Study, aimed at gaining insights into the lived experiences and long-term health outcomes of individuals with obesity, thereby enhancing scientific understanding and support for weight management.
- Integrated Care Model: Weight Watchers offers a comprehensive care model that combines medical support, nutritional guidance, and behavioral change, particularly for members using GLP-1 medications, helping them achieve significant results and improve overall health.
- Behavioral Support Impact: Data shows that GLP-1 users engaged in Weight Watchers' behavioral support program lost an average of 61.3% more weight at one month and 29.1% more at twelve months, highlighting the importance of integrating behavioral support to significantly enhance weight loss outcomes.
- Community Engagement: The Healthy Living BEYOND Weight™ Study is open to U.S. adults, and Weight Watchers leverages its strong community network to ensure more individuals can participate in research, ultimately improving obesity management and health care across various communities.
See More
WW (WW) Q4 2025 Earnings Call Transcript
See More
WW International Shares Surge 11% as Galloway Capital Discloses 8.42% Stake
- Investor Stake Increase: Galloway Capital disclosed an 8.42% stake in WW International, leading to an 11% surge in the company's stock price, indicating a market reassessment of its brand and long-term strategic potential.
- Leadership Transition: Following the abrupt departure of CEO Tara Comonte, WW International quickly established an interim CEO office led by CFO Felicia DellaFortuna and COO Jonathan Volkmann, ensuring operational continuity during this transition.
- Future Opportunities: Galloway emphasized that WW International has the chance to recruit a “transformational” CEO with expertise in consumer health, digital wellness, and subscription-based healthcare platforms, which could further drive the company's growth.
- Shareholder Value: Galloway believes WW International is worth significantly more than its current trading value and looks forward to engaging constructively with the board and management team to help unlock shareholder value.
See More
Weight Watchers Launches Ozempic® Pill for Diabetes Care
- New Drug Launch: Weight Watchers announced the addition of Novo Nordisk's Ozempic® pill through its Med+ program, further expanding its portfolio of oral GLP-1 treatments aimed at providing more options for adults with type 2 diabetes, thereby enhancing its competitive edge in the market.
- Insurance Coverage Advantage: The widespread insurance coverage of Ozempic® allows eligible members to access monthly prescription costs as low as $25, which not only reduces the financial burden on patients but also increases Weight Watchers' appeal in the diabetes management sector.
- Clinical Support System: The Weight Watchers Med+ program offers FDA-approved Ozempic® along with support from a professional clinical team, assisting members in navigating insurance and daily management, thus improving treatment outcomes.
- Significant Health Outcomes: In a study of 136 participants, the Weight Watchers diabetes nutrition program resulted in a 0.75% reduction in HbA1c levels after six months, demonstrating the program's effectiveness in improving health for diabetes patients and further solidifying Weight Watchers' market position.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
WW Plans to Prepay $40 Million Loan Ahead of Earnings Report
- Debt Prepayment: WW plans to utilize up to $40 million in cash to prepay its outstanding term loan, thereby reducing its debt burden, and expects to generate cash flow during the 'peak season marketing,' enhancing the company's financial stability.
- Q1 Expectations: Fiscal AI estimates a Q1 loss per share of $2.05 on revenue of $158.5 million, while full-year revenue is still projected between $620 million and $635 million, demonstrating the company's ability to maintain revenue stability amid challenges.
- Leadership Changes: WW recently experienced the abrupt departure of CEO Tara Comonte, and while the company is still searching for a new CEO, this change may impact strategic execution and market confidence.
- Retail Trader Reaction: On Stocktwits, retail sentiment about WW shifted from 'bullish' to 'extremely bullish,' with messaging volumes tripling over the last 24 hours, indicating a positive market response to the company's debt reduction efforts.
See More
